AMGN Amgen
FY2025 10-K
Amgen (AMGN) filed its fiscal year 2025 10-K annual report with the SEC on Feb 13, 2026. This page provides AI-powered analysis of the filing, including business overview, management discussion, risk factors, and key financial metrics from XBRL data.
AI Filing AnalysisFY2025 10-K
Business Overview
- • Core business: Biopharmaceutical company focused on innovative therapies for serious illnesses
- • NEW segment emphasis: Integration and conversion of Horizon Therapeutics' equity plans post-acquisition in October 2023
Management Discussion & Analysis
- • Cash and equivalents $9.1B in 2025 vs $12.0B in 2024, decline of $2.9B
- • Long-term debt decreased to $50.0B in 2025 from $56.5B in 2024
Risk Factors
- • Litigation risk: Ongoing U.S. Antitrust trial with Regeneron; jury awarded $135.6M compensatory damages, potential trebling to $406.8M total damages
- • Geopolitical exposure: Patent disputes in Germany and Japan with Sanofi and Regeneron, including upheld EP’004 patent validity and ongoing appeals
Financial SummaryXBRL
Revenue
$36.8B
Net Income
$7.7B
Operating Margin
24.7%
Net Margin
21.0%
ROE
89.1%
Total Assets
$90.6B
EPS (Diluted)
$14.23
Operating Cash Flow
$10.0B
Source: XBRL data from Amgen FY2025 10-K filing on SEC EDGAR. All figures in USD.
Get deeper insights on Amgen
Access full AI analysis, insider trading data, fund holdings, and cross-signal detection on SignalX.